靶向GRPR的放射性蛙皮素药物在前列腺癌诊疗中的研究进展  

Research progress of radiolabeled bombesin drugs targeting GRPR in the diagnosis and treatment of prostate cancer

作　　者：宋浩辉 徐梦欣 马旭倩 蔡杰 何超 刘冰琳 苏琪 刘志博 Song Haohui;Xu Mengxin;Ma Xuqian;Cai Jie;He Chao;Liu Binglin;Su Qi;Liu Zhibo(Boomray Pharmaceuticals Co.,Ltd,Suzhou 215011,China;College of Chemistry and Molecular Engineering,Peking University,Beijing 100871,China)

机构地区：[1]苏州博锐创合医药有限公司,苏州215011 [2]北京大学化学与分子工程学院,北京100871

出　　处：《中华核医学与分子影像杂志》2024年第12期764-768,共5页Chinese Journal of Nuclear Medicine and Molecular Imaging

摘　　要：前列腺癌是男性中最常见的癌症,也是全球男性癌症相关死亡的第五大原因。胃泌素释放肽受体(GRPR)是前列腺特异膜抗原(PSMA)的重要补充靶点,也是前列腺癌诊疗的关键靶标。放射性核素标记的蛙皮素(BBN)类似物可准确靶向肿瘤细胞过表达的GRPR,对前列腺癌病变进行早期诊疗。该文着重讨论了^(99)Tc^(m)、^(111)In、^(68)Ga、^(64)Cu、^(18)F和^(177)Lu等核素标记的用于诊断和肽受体放射性核素治疗的BBN类似物。Prostate cancer is the most common cancer among men and the fifth leading cause of cancer-related death among men worldwide.Gastrin-releasing peptide receptor(GRPR)is an important complementary target of prostate specific membrane antigen(PSMA)and a key target for prostate cancer diagnosis and treatment.Radionuclide labeled bombesin(BBN)analogues can accurately target overexpressed GRPR in tumor cells,thus providing early diagnosis and treatment of prostate cancer.In this review,we focus on the studies of^(99)Tc^(m),111In,^(68)Ga,^(64)Cu,^(18)F,and ^(177)Lu nuclide-labeled BBN analogues for diagnosis and peptide receptor radionuclide therapy.

关 键 词：前列腺肿瘤 受体 铃蟾肽 前列腺特异膜抗原 发展趋势 

分 类 号：R737.25[医药卫生—肿瘤]